SCHEMBL19041944

SCHEMBL19041944

C=C1C(=O)O[C@H]2CC3=C[C@@H](C/C(C)=C/[C@@H](OC(=O)Cc4csc5ccccc45)[C@H]12)OC3=O

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GPX4 P36969 2/20 0.75
▸ TXNRD1 Q16881 1/20 0.52
▸ GPR52 Q9Y2T5 1/20 0.42
▸ SLC22A12 Q96S37 2/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ TP53 P04637 2/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ CASP1 P29466 1/20 0.33
▸ PTPN1 P18031 2/20 0.32
▸ OPRM1 P35372 2/20 0.32
▸ OPRK1 P41145 2/20 0.32
▸ UTS2R Q9UKP6 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ CMA1 P23946 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19036321 1.00 GPX4 (0.75) GPX4TXNRD1GPR52SLC22A12SMN1; SMN2
SCHEMBL19036374 0.94 GPX4 (0.67) GPX4TXNRD1GPR52SLC22A12SMN1; SMN2
SCHEMBL19042014 0.86 GPX4 (1.00) GPX4TXNRD1GPR52KMT2A
SCHEMBL19036272 0.86 GPX4 (1.00) GPX4TXNRD1GPR52KMT2A
SCHEMBL19036298 0.86 GPX4 (1.00) GPX4TXNRD1GPR52KMT2A
SCHEMBL19036258 0.86 GPX4 (1.00) GPX4TXNRD1GPR52KMT2A
SCHEMBL19036316 0.84 GPX4 (0.76) GPX4TXNRD1GPR52SMN1; SMN2PTPN1
SCHEMBL19041921 0.84 GPX4 (0.76) GPX4TXNRD1GPR52SMN1; SMN2PTPN1
SCHEMBL19036305 0.81 GPX4 (0.71) GPX4TXNRD1GPR52PTPN1OPRK1
SCHEMBL19041925 0.80 GPX4 (0.86) GPX4TXNRD1GPR52PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3151829-B1 NOVEL SESQUITERPENE DERIVATIVES AND THEIR USE IN INFLAMMATION AND CANCER TREATMENT ACADEMIA SINICA (TW) 2019-10-02 — — EP disclosed
US-10238631-B2 Sesquiterpene derivatives and their use in inflammation or cancer treatment ACADEMIA SINICA (TW) 2019-03-26 — — US disclosed
US-20170182001-A1 NOVEL SESQUITERPENE DERIVATIVES AND THEIR USE IN INFLAMMATION OR CANCER TREATMENT THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2017-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170182001-A1 NOVEL SESQUITERPENE DERIVATIVES AND THEIR USE IN INFLAMMATION OR CANCER TREATMENT GSTK1, MIF, GSTA1 GPX4 242/4885TXNRD1 312/4885GPR52 661/4885
US-10238631-B2 Sesquiterpene derivatives and their use in inflammation or cancer treatment GSTK1, GSTA1, GTPBP10 GPX4 227/4885TXNRD1 449/4885GPR52 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback